Aligos therapeutics reports recent business progress and fourth quarter and full year 2023 financial results

South san francisco, calif., march 12, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2023.
ALGS Ratings Summary
ALGS Quant Ranking